| Name | Title | Contact Details |
|---|
Find great doctors, experts, brands and products to help you get healthier, all in one place. Our flagship location is now open and accepting patients at 632 Broadway in Manhattans NoHo neighborhood.
Evergreen Medical Technologies is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MCPN provides excellent health-related services focusing on the underserved. MCPN has one of the largest population bases of any community health center in Colorado. MCPN is dedicated to being a positive work place with employees that are committed to being focused and disciplined team members. MCPN is also dedicated to taking care of our patients and our employees to ensure the best quality of life. Career Opportunities ! MCPN is committed to quality growth and is interested in speaking with unique individuals who want more in a career. Currently we are looking for Family Practice Physicians, Physician Assistants, Nurse Practitioners, Dentists, Dental Hygienists, and other Business Professionals. We offer top compensation, world class benefits, flexible hours and a belief in work/life balance. We look forward to hearing from you! Make your career exceptional by joining us.
Scilucent is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.